JP2020533270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533270A5 JP2020533270A5 JP2019560097A JP2019560097A JP2020533270A5 JP 2020533270 A5 JP2020533270 A5 JP 2020533270A5 JP 2019560097 A JP2019560097 A JP 2019560097A JP 2019560097 A JP2019560097 A JP 2019560097A JP 2020533270 A5 JP2020533270 A5 JP 2020533270A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- receptor agonist
- serotonin receptor
- retinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 32
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 26
- 239000000018 receptor agonist Substances 0.000 claims description 12
- 229940044601 receptor agonist Drugs 0.000 claims description 12
- 206010023332 keratitis Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 206010029113 Neovascularisation Diseases 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- BGMZUEKZENQUJY-SSDOTTSWSA-N (2r)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine Chemical group COC1=CC(C[C@@H](C)N)=C(OC)C=C1I BGMZUEKZENQUJY-SSDOTTSWSA-N 0.000 claims description 4
- BGMZUEKZENQUJY-UHFFFAOYSA-N 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine Chemical group COC1=CC(CC(C)N)=C(OC)C=C1I BGMZUEKZENQUJY-UHFFFAOYSA-N 0.000 claims description 4
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical class NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 201000007737 Retinal degeneration Diseases 0.000 claims description 4
- 206010038848 Retinal detachment Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 201000000159 corneal neovascularization Diseases 0.000 claims description 4
- 229960002963 ganciclovir Drugs 0.000 claims description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 208000005100 Herpetic Keratitis Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical class N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 2
- 206010038910 Retinitis Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical class N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960000724 cidofovir Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical class N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001447 fomivirsen Drugs 0.000 claims description 2
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 claims description 2
- 229960005102 foscarnet Drugs 0.000 claims description 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
- 208000037805 labour Diseases 0.000 claims description 2
- 229960001179 penciclovir Drugs 0.000 claims description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000004263 retinal angiogenesis Effects 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 229960003962 trifluridine Drugs 0.000 claims description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960002149 valganciclovir Drugs 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000556 agonist Substances 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492841P | 2017-05-01 | 2017-05-01 | |
| US62/492,841 | 2017-05-01 | ||
| PCT/US2018/030448 WO2018204359A1 (en) | 2017-05-01 | 2018-05-01 | Compositions and methods for treating ocular pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533270A JP2020533270A (ja) | 2020-11-19 |
| JP2020533270A5 true JP2020533270A5 (enExample) | 2021-05-27 |
Family
ID=64017034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560097A Pending JP2020533270A (ja) | 2017-05-01 | 2018-05-01 | 眼の病態を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11759438B2 (enExample) |
| EP (1) | EP3618850A4 (enExample) |
| JP (1) | JP2020533270A (enExample) |
| KR (2) | KR20230135163A (enExample) |
| CN (1) | CN110662549A (enExample) |
| AU (2) | AU2018263853A1 (enExample) |
| CA (1) | CA3061900A1 (enExample) |
| WO (1) | WO2018204359A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4230195A1 (en) * | 2019-03-07 | 2023-08-23 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| WO2023048174A1 (ja) * | 2021-09-22 | 2023-03-30 | テイカ製薬株式会社 | 角膜疾患治療剤 |
| WO2024010765A1 (en) * | 2022-07-05 | 2024-01-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions for treating 5-ht2 conditions and methods of using the same |
| DE23753884T1 (de) | 2022-08-04 | 2025-08-14 | Synex Holdings Bv | Prodrugs von substituierten Ergolinen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554617A (en) * | 1979-09-28 | 1996-09-10 | The Upjohn Company | Method for treating cancer with 6-aryl pyrimidine compounds |
| US5545617A (en) | 1993-11-12 | 1996-08-13 | The Schepens Eye Research Institute, Inc. | Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion |
| AU3708295A (en) * | 1994-11-04 | 1996-05-31 | Stefan L. Marklund | Use of receptor agonists to stimulate superoxide dismutase activity |
| US20090191288A1 (en) * | 1996-02-12 | 2009-07-30 | Squires Meryl J | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases |
| JPH1067684A (ja) * | 1996-06-17 | 1998-03-10 | Mitsubishi Chem Corp | 涙液分泌促進剤 |
| EP0813878B1 (en) * | 1996-06-17 | 2002-02-06 | Mitsubishi Chemical Corporation | Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds |
| US20030207890A1 (en) * | 2001-02-23 | 2003-11-06 | Collier Robert J | Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US20060069124A1 (en) | 2004-09-07 | 2006-03-30 | Rao P S | Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases |
| TNSN08110A1 (en) * | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
| US8859579B2 (en) | 2008-03-21 | 2014-10-14 | Richard Andrew Sewell | Compostions and methods for preventing and/or treating disorders associated with cephalic pain |
| US9642819B2 (en) | 2008-07-10 | 2017-05-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical | Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation |
| US9271980B2 (en) * | 2009-08-03 | 2016-03-01 | Daljit Singh Dhanoa | Deuterium-enriched pyrimidine compounds and derivatives |
| CA2855941A1 (en) * | 2011-11-14 | 2013-05-23 | Advanced Cell Technology, Inc. | Pharmaceutical preparations of human rpe cells and uses thereof |
| WO2014003850A2 (en) * | 2012-06-26 | 2014-01-03 | Timothy Paul Foster | Methods for treatment of ocular diseases |
| US11033554B2 (en) * | 2015-07-24 | 2021-06-15 | United States Government As Represented By The Department Of Veterans Affairs | Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration |
-
2018
- 2018-05-01 AU AU2018263853A patent/AU2018263853A1/en not_active Abandoned
- 2018-05-01 JP JP2019560097A patent/JP2020533270A/ja active Pending
- 2018-05-01 EP EP18794658.7A patent/EP3618850A4/en not_active Withdrawn
- 2018-05-01 KR KR1020237030827A patent/KR20230135163A/ko not_active Ceased
- 2018-05-01 US US16/610,382 patent/US11759438B2/en active Active
- 2018-05-01 CN CN201880034321.XA patent/CN110662549A/zh active Pending
- 2018-05-01 KR KR1020197035398A patent/KR20200003110A/ko not_active Ceased
- 2018-05-01 CA CA3061900A patent/CA3061900A1/en active Pending
- 2018-05-01 WO PCT/US2018/030448 patent/WO2018204359A1/en not_active Ceased
-
2024
- 2024-02-12 AU AU2024200866A patent/AU2024200866A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533270A5 (enExample) | ||
| CN111163757B (zh) | 眼用制剂 | |
| JP6494528B2 (ja) | フッ化インテグリンアンタゴニスト | |
| CN107708738B (zh) | 含有柠檬酸酯的贮库制剂 | |
| JP2014533275A5 (enExample) | ||
| CN101678006A (zh) | 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂 | |
| JP2011530496A (ja) | 眼新生血管形成症状の治療のためのソラフェニブを含む眼科用医薬組成物 | |
| JP2021503449A5 (enExample) | ||
| US12370209B2 (en) | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | |
| CN115103842A (zh) | 用于治疗眼部疾病的组合物 | |
| JP2025106418A (ja) | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 | |
| ME02608B (me) | Kombinacija, komplet i postupak snižavanja intraokularnog pritiska | |
| CN110662549A (zh) | 用于治疗眼病的组合物和方法 | |
| JP2021138710A5 (enExample) | ||
| JP2020530459A5 (enExample) | ||
| JP2019534269A5 (enExample) | ||
| JP2009517375A (ja) | 眼の疾患の治療 | |
| JP2020114847A5 (enExample) | ||
| HK40073052A (en) | Medical use of 5'-adenosine diphosphate ribose (adpr) | |
| JP2016172730A (ja) | ポリペプチドを含有する医薬組成物 | |
| AU2023221950A1 (en) | Treatment of anatomical and functional retinal atrophies | |
| JP2014193854A (ja) | テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤 | |
| JPWO2012066994A1 (ja) | 神経保護作用を持つ薬剤配合 | |
| CN106456641A (zh) | 眼后段疾病的预防或治疗剂 | |
| JPWO2019173744A5 (enExample) |